Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters

Apply

Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters

Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 2

Abstract

To investigate bioequivalence (BE) testing of an acarbose formulation in healthy Chinese volunteers through the use of recommended and innovative pharmacodynamic (PD) parameters. Following the Food and Drug Administration (FDA) guidance, a randomized, cross-over study of acarbose test (T) and reference (R) (Glucobay®) formulations was performed with a 1-week wash-out period. Preliminary pilot studies showed that the appropriate dose of acarbose was 2 × 50 mg, and the required number of subjects was 40. Serum glucose concentrations after sucrose administration (baseline) and co-administration of sucrose/acarbose on the following day were both determined. Three newly defined PD measures of glucose fluctuation (glucose excursion (GE), GE′ (glucose excursion without the effect of the homeostatic glucose control), and fAUC (degree of fluctuation of serum glucose based on AUC)), the plateau glucose concentration (Css), and time of maximum reduction in glucose concentration (Tmax) were tested in the evaluation. The adequacy of the two parameters recommended by the FDA, ΔCSG,max (maximum reduction in serum glucose concentration) and AUEC(0-4h) (reduction in the AUC(0-4h) of glucose between baseline and acarbose formulation) was also evaluated. The Tmax values were comparable, and the 90% confidence intervals of the geometric test/reference ratios (T/R) for ΔCSG,max, Css, GE, and fAUC were all within 80–125%. The parameter GE′ was slightly outside the limits, and the parameter AUEC(0-4h) could not be computed due to the presence of negative values. In acarbose BE evaluation, while the recommended parameter ΔCSG,max is valuable, the combination of Css and one of the newly defined glucose fluctuation parameters, GE, GE’, and fAUC is preferable than AUEC(0-4h). The acarbose test formulation can be initially considered to be bioequivalent to Glucobay®.

Authors and Affiliations

Min Zhang, Jin Yang, Lei Tao, Lingjun Li, Pengcheng Ma, John Paul Fawcett

Keywords

Role of Glycosylation in Conformational Stability, Activity, Macromolecular Interaction and Immunogenicity of Recombinant Human Factor VIII

Factor VIII (FVIII) is a multi-domain glycoprotein that is an essential cofactor in the blood coagulation cascade. Its deficiency or dysfunction causes hemophilia A, a bleeding disorder. Replacement using exogenous recom...

Target-Mediated Disposition Model Describing the Dynamics of IL12 and IFNγ after Administration of a Mifepristone-Inducible Adenoviral Vector for IL-12 Expression in Mice

The online version of this article (doi:10.1208/s12248-012-9423-9) contains supplementary material, which is available to authorized users.

EP ID EP681211
DOI 10.1208/s12248-012-9341-x
Views 58
Downloads 0